Targeting EBV-positive diffuse large B-cell lymphoma using new therapeutic approaches
PROTAC-based direct and oncolytic killing of EBV+ DLBCLs through synthetic lethality
['FUNDING_U01'] · UNIVERSITY OF FLORIDA · NIH-11074212
This study is looking at new ways to treat a type of lymphoma linked to the Epstein-Barr virus, especially for people with weakened immune systems, like those with HIV, by finding out how the virus changes cancer cells and using that knowledge to make treatments more effective.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-11074212 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative treatments for diffuse large B-cell lymphoma (DLBCL) that is associated with the Epstein-Barr virus (EBV), particularly in patients with compromised immune systems like those living with HIV. The approach involves understanding how EBV alters DNA repair mechanisms in cancer cells, making them vulnerable to specific therapeutic agents that exploit these weaknesses. By targeting these vulnerabilities, the research aims to improve treatment outcomes for patients with this aggressive form of lymphoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with EBV-positive diffuse large B-cell lymphoma, especially those who are also living with HIV.
Not a fit: Patients with DLBCL who are not infected with the Epstein-Barr virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with EBV-positive DLBCL, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar vulnerabilities in cancer cells, suggesting that this approach could be effective.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BHADURI-MCINTOSH, SUMITA — UNIVERSITY OF FLORIDA
- Study coordinator: BHADURI-MCINTOSH, SUMITA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, Cancers